Cover Image
市場調查報告書

微生物治療藥市場:2015-2030年

Microbiome Therapeutics Market, 2015 - 2030

出版商 ROOTS ANALYSIS 商品編碼 350407
出版日期 內容資訊 英文 218 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
微生物治療藥市場:2015-2030年 Microbiome Therapeutics Market, 2015 - 2030
出版日期: 2016年01月15日 內容資訊: 英文 218 Pages
簡介

本報告提供微生物治療藥市場現況與展望的相關調查,開發階段、產品類型、各適應症的治療藥開發平台,潛在的治療領域的流行病學、患者人口、可利用的治療計劃,近幾年的聯盟,微生物治療藥的普及預定,以及主要企業的簡介等彙整。

第1章 序章

第2章 摘要整理

第3章 簡介

  • 微生物叢、微生物定義
  • 人體微生物的發現
  • 人體微生物計劃 (HMP)
  • 人體微生物的功能
  • 腸內菌叢
  • 嬰兒的微生物叢的發達
  • 人體微生物和疾病的關係
  • 微生物治療藥的需求
  • 糞便細菌製劑療法:回復健康的腸內微生物叢的強力手段

第4章 市場概要

  • 本章概要
    • 微生物治療藥的開發平台
    • 糞便微生物叢移植的開發平台
    • 診斷應用程式的開發開發平台
    • 醫療食、補充品及消費品的開發平台

第5章 KOL分析

  • 本章概要
  • 益生菌醫藥品
  • 益生元醫藥品
  • 益生菌/益生元醫藥品的開發平台開發

第6章 主要治療領域

  • 本章概要
  • 腸胃 (GI) 疾病/消化器官疾病
    • 梭狀芽孢桿菌-難辨感染疾病 (CDI)
    • 大腸躁鬱症 (IBS)
  • 發炎性疾病
    • 潰瘍性結腸炎
    • 克隆氏症
  • 代謝異常
    • 糖尿病
    • 肥胖
  • 婦產科疾病
    • 細菌性陰道炎 (BV)

第7章 創業投資的關心

  • 本章概要
  • 微生物治療藥、診斷的開發資金的案例
  • 創業投資的關注高漲
  • 資金範例:資金類型的分佈
  • 主要企業:資金案例數的分佈
  • 最活躍的VC企業/機關
  • 資金的大部分以治療用途為目標

第8章 近幾年的合作

  • 本章概要
  • 聯盟模式/協定
  • 微生物治療藥:近幾年的合作
  • 分佈:各月/各年度
  • 分佈:各應用類型
  • 分佈:各聯盟類型
  • 使用複數合作的最活躍企業

第9章 市場規模、機會分析

  • 本章概要
  • 預測手法
  • 微生物治療藥市場:主要的前提條件
  • 微生物治療藥市場:機會分析

第10章 企業簡介

  • 本章概要
  • C3 Jian
  • Enterome Bioscience
  • Immuron
  • MicroBiome Therapeutics
  • OpenBiome
  • Osel
  • Rebiotix
  • Ritter Pharmaceuticals
  • Second Genome
  • Seres Therapeutics
  • Synthetic Biologics

第11章 結論

第12章 專家的採訪

第13章 附錄1:表格資料

第14章 附錄2:企業、組織清單

圖表

目錄
Product Code: RA10053

The term “microbiota” refers to specific clusters of commensal, symbiotic and pathogenic microorganisms that reside in various regions on and within the human body. The human microbiome is involved in various functions that are essential to lead a healthy life. Majority of the microorganisms benefit humans by supplementing them with traits that they would otherwise not possess. These include metabolism of complex carbohydrates, renewal of gut epithelial cells and prevention of growth of pathogens. However, several microorganisms are associated with pathogenic organisms or have the capability of translating into a disease-causing microbe.In fact, an imbalance in the human flora or dysbiosis is also seen to be associated with several long-term diseases. During dysbiosis, it is observed that with the reducing number of beneficial microbes, there is a concurrent increase in the number of harmful microbes. The increase in the number of pathogenic microbes further leads to the development of several harmful diseases such as inflammatory bowel disease (IBD), cancer, bacterial vaginosis (BV), obesity and chronic fatigue syndrome.

In addition to the existing treatment plans for such health conditions, approaches that modify natural formulations by adding or removing individual microbes or entire microbial communities have been shown to have a significant impact on the health of an individual. Usingmicrobiome as a therapy has unique advantages over traditional small molecules or biologics.It can be used to identify individual therapeutic microorganisms and help in designing the therapies customised to the patient's microbiome. Unlike the adverse effects posed by the prolonged use of drugs such as the antibiotics, microbiome therapeutics have a lower risk of toxicity associated with them. In addition, microbiome based therapies provide a rich source of new biomarkers helping in the classification of the patients into relatively homogeneous subpopulations.

Currently, there are many popular probiotics, prebiotics, medical food and supplements commercially available in the market as OTC products. These products are known to prevent a number of diseases by restoring the human microbiome to its natural state. However, these products cannot be used as a replacement for medication or as a treatment for the eradication of the disease. The overall microbiome therapeutics market is still in its infancy with no approved drugs; Faecal microbial transplant (FMT) is the only microbiome related therapy that has entered the market. With several firms and investors displaying a growing interest in this field, the overall market holds a strong potential in the coming years.

Synopsis:

The ‘Microbiome Therapeutics Market, 2015-2030' report provides a comprehensive study on the current landscape and the future outlook of the evolving pipeline of products in this area. Imbalance in the natural microbiota are a known cause for many chronic diseases such as antibiotic associated diarrhoea (AAD), Clostridium difficileinfections (CDI), irritable bowel syndrome (IBS), diabetes, Crohn's disease and ulcerative colitis. While the field has gathered the interest of several companies, there are no approved microbiome drugs available in the market yet; FMT is the only commercially available therapy. The development pipeline of microbiome therapeutics, though, has several promising candidates that are likely to result in commercial success stories in the foreseen future.

Among other elements, the report also elaborates on new microbiome based diagnostic solutions being developed and the upcoming opportunities in this market for different stakeholders. As pharmaceutical companies continue to initiate and expand their research programs in this area, one of the key objectives outlined for this report was to understand the future potential of the market. This was done by analysing:

  • The microbiome therapeutic pipeline in terms of phase of development, type of products and indications.
  • The epidemiology, patient population and available treatment plans for the potential therapeutic areas in this field.
  • Partnerships that have taken place in the recent past covering research and development collaborations, product development and commercialisation agreements, license agreements, acquisitions and other relevant agreements.
  • Various investments and grants received by companies focused in this area.
  • The likely adoption of the microbiome therapeutics, the competition posed by the current treatment plans and the expected growth rate over the coming few years.

The study provides a detailed market forecast and opportunity analysis for the short-mid term (2015-2022) and long term (2022-2030). The research, analysis and insights presented in this report include potential sales of FMT therapies and drugs in late stages of development. Our opinions and insights, presented in this study, were influenced by several discussions we conducted with experts in this area. These included senior representatives at Assembly Biosciences, Da Volterra, Metabiomics, MicroBiome Therapeutics and Rebiotix. All actual figures have been sourced and analysed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights:

  • 1. Overall, we have identified more than 100 microbiome products, in clinical and preclinical stages,which are being developed as therapeutic interventions for various disease areas. A healthy 27% of the pipeline accounts for molecules in clinical development; of these, majority are in phase II.
  • 2. In addition, we have captured several start-ups and small-sized firms that have taken initiatives in developing innovative microbiome based therapeutics. Notable examples include (in alphabetical order) AOBiome, Avid Biotics, C3 Jian, Da Volterra, OpenBiome, Procarta Biosystems, Rebiotix, Ritter Pharmaceuticals, Quorum Innovations, Seres Therapeutics, Symbiotic Health, Vedanta Biosciences, Xycrobe Therapeutics.
  • 3. Several firms are also developing microbiome related diagnostics and companion diagnostics. Examples include (in alphabetical order) Admera Health, Biocartis, Enterome Bioscience, Human Longevity, Metabiomics, Microbiome Diagnostics, Viomer, Whole Biome.
  • 4. Encouraging clinical results and unexplored opportunities have yielded an intense framework of investment activity with a sizeable number of venture capitalists actively supporting the research. In fact, during 2014 and 2015, there have been investments (equity + debt) of close to USD 0.7 billion.
  • 5. The microbiome therapeutics market is anticipated to grow aggressively with a healthy annual growth rate of 73% between 2015 and 2030. In the longer term, we expect the market to continue to rise steadily with high adoption rates of existing FMTs and emergence of novel microbiome related products.
  • 6. Additional analysis suggeststhat metabolic disorders and gastrointestinal (GI) disorders are the key therapeutic areas likely to garner a significant proportion of the overall market.

Research Methodology:

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines:

Chapter 2 provides an executive summary of the report. It offers a high level view on where the microbiome therapeutics market is headed in the mid to long term.

Chapter 3 provides a general introduction to the underlying concepts on the human microbiota. In addition to reviewing the function of microbiota, we have also discussed key aspects of the human microbiome project and the diseases caused by imbalance in the microbiota. Further, we have highlighted the need for microbiome therapeutics along with a brief description of the existing FMT therapies.

Chapter 4 includes information on over 100 molecules that are currently in different stages of development (both clinical and preclinical/discovery). In this section, we have presented a detailed analysis of the microbiome therapeutics development pipeline including information on the phase of development, indications and the type of products. In addition, the chapter contains details on different microbiome based diagnostics, medical foods and over-the-counter (OTC) supplements that are approved or under development.

Chapter 5 provides information on the various types of probiotic and prebiotic drugs that are being developed as microbiome therapeutics. It features a detailed discussion on their mode of action, range of formulations and the different disease areas likely to benefit from the use of these drugs.

Chapter 6 highlights the promising therapeutic areas for microbiome therapeutics. These indications are the prime focus of companies developing microbiome based drugs. The chapter also highlights the epidemiological facts and currently available treatment options for each indication.These therapeutic areas include gastrointestinal (GI) disorders, inflammatory disorders, metabolic disorders and women disorders.

Chapter 7 presents details on various investments and grants received by companies focused in the area of microbiome therapeutics. The analysis highlights the growing interest of the VC community and other strategic investors in this market.

Chapter 8 features an elaborate discussion on the collaborations and partnerships that have been forged amongst players in this market. We have also discussed the various partnership models in existence and the most common forms of deals/agreements that have evolved over time.

Chapter 9 highlights the monetary opportunity presented by these therapies.The analysis highlights the likely evolution of important parameters such as the target patient population and the likely market penetration rates. We have also presented an indicative distribution of the overall market across the well-known therapeutic areas.

Chapter 10 provides detailed company and drug profiles of the leading players in the market. Each profile includes information such as the company's financial performance (wherever available), geographical presence, pipeline of microbiome therapeutics and recent collaborations.

Chapter 11 summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 12 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. These include JP Benya (Vice President, Business Development of Assembly Biosciences),Pierre-Alain Bandinelli (Chief Business Officer of Da Volterra), Gregory J. Kuehn (Vice President, Business Development and Marketing of Metabiomics), Dr. Mark Heiman (Vice President of Research and Chief Scientific Officer of MicroBiome Therapeutics) and Lee Jones (President and CEO of Rebiotix).

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter14 is an appendix, which provides the list of companies and organisations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Defining Microbiota and Microbiome
  • 3.2. Discovery of the Human Microbiome
  • 3.3. The Human Microbiome Project (HMP)
    • 3.3.1. Project Approach
    • 3.3.2. Project Initiatives
    • 3.3.3. Project Achievements
  • 3.4. Functions of the Human Microbiome
  • 3.5. The Gut Flora
    • 3.5.1. Role of Gut Microbiota
    • 3.5.2. Imbalance in the Gut Flora
  • 3.6. Development of Microbiota in Infants
    • 3.6.1. Mode of Delivery
    • 3.6.2. Type of Feeding
    • 3.6.3. Use of Antibiotics by the Mother
  • 3.7. Relationship between the Human Microbiome and Diseases
    • 3.7.1. Cancer
    • 3.7.2. Inflammatory Bowel Disease (IBD)
    • 3.7.3. Obesity
    • 3.7.4. Type-2 Diabetes
  • 3.8. Need for Microbiome Therapies
  • 3.9. Faecal Bacteriotherapy: A Powerful Tool to Restore Healthy Gut Microflora
    • 3.9.1. FMT and FDA Regulation

4. MICROBIOME THERAPEUTICS AND DIAGNOSTICS: MARKET LANDSCAPE

  • 4.1. Chapter Overview
    • 4.1.1. Development Pipeline of Microbiome Therapeutics
      • 4.1.1.1. Distribution by Phase of Development
      • 4.1.1.2. Distribution by Type of Product
      • 4.1.1.3. Distribution by Geography
      • 4.1.1.4. Distribution by Therapeutic Area
      • 4.1.1.5. Active Industry Players
    • 4.1.2. Development Pipeline of Faecal Microbiota Transplant
    • 4.1.3. Development Pipeline of Diagnostic Applications
    • 4.1.4. Development Pipeline of Medical Food, Supplements and Consumer Products

5. PROBIOTIC AND PREBIOTIC DRUGS

  • 5.1. Chapter Overview
  • 5.2. Probiotic Drugs
    • 5.2.1. Introduction
    • 5.2.2. Types of Probiotics
    • 5.2.3. Therapeutic Areas Benefiting from Probiotics
      • 5.2.3.1. Antibiotic-Associated Diarrhoea (AAD)
      • 5.2.3.2. Infectious Childhood Diarrhoea
      • 5.2.3.3. Cholesterol
      • 5.2.3.4. Inflammatory Bowel Disease (IBD)
      • 5.2.3.5. Blood Pressure
      • 5.2.3.6. Lactose Intolerance
      • 5.2.3.7. Weight Loss
      • 5.2.3.8. Vitamin Production
      • 5.2.3.9. Bacterial Vaginosis (BV)
    • 5.2.4. Side Effects of Probiotics
  • 5.3. Prebiotic Drugs
    • 5.3.1. Introduction
    • 5.3.2. Source of Prebiotics
    • 5.3.3. Types of Prebiotics
      • 5.3.3.1. Fructo-Oligosaccharides
      • 5.3.3.2. Galacto-Oligosaccharides
      • 5.3.3.3. Inulin
    • 5.3.4. Therapeutic Areas Benefiting from Prebiotics
      • 5.3.4.1. Antibiotic Associated Diarrhoea (AAD)
      • 5.3.4.2. Constipation
      • 5.3.4.3. Gastrointestinal (GI) Disorders
    • 5.3.5. Dysbiosis
  • 5.4. Development Pipeline of Probiotic/Prebiotic Drugs
    • 5.4.1. Distribution by Phase of Development
    • 5.4.2. Distribution by Therapeutic Area
    • 5.4.3. Distribution by Geography
    • 5.4.4. Distribution by Company

6. KEY THERAPEUTIC AREAS

  • 6.1. Chapter Overview
  • 6.2. Gastrointestinal (GI) Disorders
    • 6.2.1. Clostridium difficile Infections (CDI)
      • 6.2.1.1. Disease Description
      • 6.2.1.2. Epidemiology
      • 6.2.1.3. Current Treatment Plans
      • 6.2.1.4. Microbiome Therapies for CDIs and Other Hospital Acquired Diseases
    • 6.2.2. Irritable Bowel Syndrome (IBS)
      • 6.2.2.1. Disease Description
      • 6.2.2.2. Epidemiology
      • 6.2.2.3. Current Treatment Plans
      • 6.2.2.4. Microbiome Therapies for IBS
  • 6.3. Inflammatory Disorders
    • 6.3.1. Ulcerative Colitis
      • 6.3.1.1. Disease Description
      • 6.3.1.2. Epidemiology
      • 6.3.1.3. Current Treatment Plans
      • 6.3.1.4. Microbiome Therapies for Ulcerative Colitis
    • 6.3.2. Crohn's Disease
      • 6.3.2.1. Disease Description
      • 6.3.2.2. Epidemiology
      • 6.3.2.3. Current Treatment Plans
      • 6.3.2.4. Microbiome Therapies for Crohn's Disease
  • 6.4. Metabolic Disorders
    • 6.4.1. Diabetes
      • 6.4.1.1. Disease Description
      • 6.4.1.2. Epidemiology
      • 6.4.1.3. Current Treatment Plans
      • 6.4.1.4. Microbiome Therapies for Diabetes
    • 6.4.2. Obesity
      • 6.4.2.1. Disease Description
      • 6.4.2.2. Epidemiology
      • 6.4.2.3. Current Treatment Plans
      • 6.4.2.4. Microbiome Therapies for Obesity
  • 6.5. Women Disorders
    • 6.5.1. Bacterial Vaginosis (BV)
      • 6.5.1.1. Disease Description
      • 6.5.1.2. Epidemiology
      • 6.5.1.3. Current Treatment Plans
      • 6.5.1.4. Microbiome Therapies for BV

7. VENTURE CAPITAL INTEREST

  • 7.1. Chapter Overview
  • 7.2. Instances of Funding for Development of Microbiome Therapeutics and Diagnostics
  • 7.3. Rising Venture Capital Interest
  • 7.4. Funding Instances: Distribution by Type of Funding
  • 7.5. Leading Players: Distribution by Number of Funding Instances
  • 7.6. Most Active VC Firms/Institutions
  • 7.7. Most of the Funding is Targeted Towards Therapeutic Applications

8. RECENT COLLABORATIONS

  • 8.1. Chapter Overview
  • 8.2. Partnership Models/Agreements
  • 8.3. Microbiome Therapies: Recent Collaborations
  • 8.4. Distribution by Month/Year
  • 8.5. Distribution by Type of Application
  • 8.5.1. Distribution by Type of Therapeutic Product
  • 8.6. Distribution by Type of Partnership
  • 8.7. Most Active Companies with Multiple Collaborations

9. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Forecast Methodology
  • 9.3. Microbiome Therapeutics Market: Key Assumptions
  • 9.4. Microbiome Therapeutics Market: Opportunity Analysis
    • 9.4.1. Overall Microbiome Therapeutics Market, 2015-2030
    • 9.4.2. Microbiome Therapeutics Market, 2015-2030: Distribution by Therapeutic Area
    • 9.4.3. Microbiome Therapeutics Market, 2015-2030: Distribution by Application

10. COMPANY PROFILES

  • 10.1. Chapter Overview
  • 10.2. C3 Jian
    • 10.2.1. Company Overview
    • 10.2.2. Product Portfolio
      • 10.2.2.1. Therapeutics
      • 10.2.2.2. Diagnostics
  • 10.3. Enterome Bioscience
    • 10.3.1. Company Overview
    • 10.3.2. Product Portfolio
      • 10.3.2.1. Therapeutics
      • 10.3.2.2. Diagnostics
    • 10.3.3. Collaborations
  • 10.4. Immuron
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Portfolio
    • 10.4.4. Collaborations
  • 10.5. MicroBiome Therapeutics
    • 10.5.1. Company Overview
    • 10.5.2. Product Portfolio
  • 10.6. OpenBiome
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Portfolio
  • 10.7. Osel
    • 10.7.1. Company Overview
    • 10.7.2. Product Portfolio
    • 10.7.3. Collaborations
  • 10.8. Rebiotix
    • 10.8.1. Company Overview
    • 10.8.2. Product Portfolio
    • 10.8.3. Collaborations
  • 10.9. Ritter Pharmaceuticals
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Portfolio
    • 10.9.4. Collaborations
  • 10.10. Second Genome
    • 10.10.1. Company Overview
    • 10.10.2. Second Genome Solutions
    • 10.10.3. Product Portfolio
    • 10.10.4. Collaborations
  • 10.11. Seres Therapeutics
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Portfolio
    • 10.11.4. Collaborations
  • 10.12. Synthetic Biologics
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Portfolio
    • 10.12.4. Collaborations/Recent Developments

11. CONCLUSION

  • 11.1. Imbalance in the Human Microbiota Leading to Rising Chronic Disorders
  • 11.2. Increasing Antibiotic Use is The Primary Cause of Microflora Disturbance
  • 11.3. Microbiome Therapy Offers a Potential Solution to Preserve the Human Microflora
  • 11.4. Several Initiatives are Still in Early Stages of Development
  • 11.5. An Active Support from Regulatory Authorities Likely to Drive High Accessibility
  • 11.6. With a Strong Preclinical Backup, We Expect Steady Growth in the Coming Years

12. INTERVIEW TRANSCRIPTS

  • 12.1. Chapter Overview
  • 12.2. JP Benya, Vice President, Business Development, Assembly Biosciences
  • 12.3. Pierre-Alain Bandinelli, Chief Business Officer, Da Volterra
  • 12.4. Gregory J. Kuehn, Vice President, Business Development and Marketing, Metabiomics
  • 12.5. Dr. Mark Heiman, Vice President of Research and Chief Scientific Officer, MicroBiome Therapeutics
  • 12.6. Lee Jones, President and CEO, Rebiotix

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS

List of Figures

  • Figure 3.1: Achievements of the Human Microbiome Project
  • Figure 3.2: Factors Affecting the Gut Flora
  • Figure 3.3: Factors Affecting the Infant Gut Microbiota
  • Figure 4.1: Microbiome Therapeutics: Distribution by Phase of Development
  • Figure 4.2: Microbiome Therapeutics: Distribution by Type of Product
  • Figure 4.3: Microbiome Therapeutics: Distribution by Geography
  • Figure 4.4: Microbiome Therapeutics: Distribution by Therapeutic Area
  • Figure 4.5: Microbiome Therapeutics: Distribution by Therapeutic Area and Phase of Development
  • Figure 4.6: Microbiome Therapeutics: Active Industry Players
  • Figure 5.1: Probiotic Drugs: Modes of Action
  • Figure 5.2: Probiotic and Prebiotic Drugs: Distribution by Number of Products
  • Figure 5.3: Probiotic and Prebiotic Drugs: Distribution by Phase of Development
  • Figure 5.4: Probiotic and Prebiotic Drugs: Distribution by Therapeutic Area
  • Figure 5.5: Probiotic and Prebiotic Drugs: Distribution by Geography
  • Figure 5.6: Probiotic and Prebiotic Drugs: Active Industry Players
  • Figure 6.1: Clostridium difficile Infections (CDI): Pipeline by Product Type and Development Stage
  • Figure 6.2: Irritable Bowel Syndrome (IBS): Pipeline by Product Type and Development Stage
  • Figure 6.3: Diabetes: Pipeline by Product Type and Development Stage
  • Figure 7.1: Number of Funding Instances by Year, 2005 Onwards
  • Figure 7.2: Amount Invested by Year, 2005 Onwards
  • Figure 7.3: Funding Instances: Distribution by Type, 2005-2015
  • Figure 7.4: Funding Instances: Distribution by Total Amount Invested, 2005-2015 (USD Million)
  • Figure 7.5: Funding Instances: Distribution by Range of Amount Invested by Type of Funding (USD Million)
  • Figure 7.6: Most Active Players: Distribution by Number of Funding Instances, 2005-2015
  • Figure 7.7: Most Active VC Firms/Investors: Distribution by Number of Instances, 2005, 2015
  • Figure 7.8: Funding Instances: Distribution by Type of Application
  • Figure 7.9: Funding Instances: Distribution by Type of Product
  • Figure 8.1: Recent Collaborations: Distribution by Year
  • Figure 8.2: Recent Collaborations: Distribution by Type of Application
  • Figure 8.3: Recent Collaborations: Distribution by Type of Therapeutic Product
  • Figure 8.4: Recent Collaborations: Distribution by Type of Model
  • Figure 8.5: Recent Collaborations: Distribution by Company
  • Figure 9.1: Microbiome Therapeutics Market Forecast (USD Million), Short Term, Base Case, 2015 - 2022
  • Figure 9.2: Microbiome Therapeutics Market Forecast (USD Million), Mid-Long Term, Base Case, 2022 - 2030
  • Figure 9.3: Microbiome Therapeutics Market: Distribution by Therapeutic Area, 2025, 2030
  • Figure 9.4: Microbiome Therapeutics Market: Distribution by Function, 2030
  • Figure 10.1: Advantages of Different Formulations of C16G2
  • Figure 10.2: OpenBiome: Revenues 2014, Distribution by Different Segments (USD Million)
  • Figure 10.3: Second Genome Solutions Program
  • Figure 11.1: Microbiome Therapeutics Market (USD Million), 2015, 2022, 2030

List of Tables

  • Table 3.1: Microbiota in the GI Tract
  • Table 4.1: Microbiome Therapeutics: Development Pipeline
  • Table 4.2: FMT Therapies: Development Pipeline
  • Table 4.3: Microbiome Diagnostics: Development Pipeline
  • Table 4.4: Microbiome Based Medical Food Supplements and Consumer Products for Humans: Development Pipeline
  • Table 5.1: Foods Containing Prebiotics
  • Table 5.2: Probiotic and Prebiotic Drugs: Development Pipeline
  • Table 6.1: Clostridium difficile Infections (CDI): Diagnostic Tests
  • Table 6.2: Clostridium difficile Infections (CDI) and Other Hospital Acquired Infections: Microbiome Therapeutics Pipeline
  • Table 6.3: Irritable Bowel Syndrome (IBS): Current Medication
  • Table 6.4: Irritable Bowel Syndrome (IBS): Microbiome Therapeutics Pipeline
  • Table 6.5: Ulcerative Colitis: Microbiome Therapeutics Pipeline
  • Table 6.6: Crohn's Disease: Current Medication
  • Table 6.7: Crohn's Disease: Microbiome Therapeutics Pipeline
  • Table 6.8: Diabetes: Current Medications
  • Table 6.9: Diabetes: Microbiome Therapeutics Pipeline
  • Table 6.10: Obesity: Microbiome Therapeutics Pipeline
  • Table 6.11: Bacterial Vaginosis (BV): Current Medication
  • Table 6.12: Bacterial Vaginosis (BV): Microbiome Therapeutics Pipeline
  • Table 7.1: List of Funding Instances and Investors, 2005-2015
  • Table 7.2: Types of Funding Instances, 2005- 2015
  • Table 7.3: Amount Invested by Product Type, 2005- 2015 (USD Million)
  • Table 8.1: Microbiome Therapies: Recent Collaborations (2005-2015)
  • Table 9.1: Potential Therapeutic Areas: Estimated Market Growth Rate
  • Table 9.2: Potential Therapeutic Areas: Estimated Penetration (By 2030)
  • Table 10.1: C3 Jian: Product Portfolio, Microbiome Therapeutics
  • Table 10.2: Different Formulations of C16G2
  • Table 10.3: C3 Jian: Product Portfolio, Microbiome Diagnostics
  • Table 10.4: Enterome Bioscience: Product Portfolio, Microbiome Therapeutics
  • Table 10.5: Enterome Bioscience: Product Portfolio, Microbiome Diagnostics
  • Table 10.6: Immuron: Product Portfolio, Microbiome Therapeutics
  • Table 10.7: MicroBiome Therapeutics: Product Portfolio, Microbiome Therapeutics
  • Table 10.8: OpenBiome: Product Portfolio, FMT
  • Table 10.9: FMP 30: Specifications
  • Table 10.10: FMP 250: Specifications
  • Table 10.11: Osel: Product Portfolio, Microbiome Therapeutics
  • Table 10.12: Rebiotix: Product Portfolio, Microbiome Therapeutics
  • Table 10.13: Ritter Pharmaceuticals: Product Portfolio, Microbiome Therapeutics
  • Table 10.14: Second Genome: Product Portfolio, Microbiome Therapeutics
  • Table 10.15: Seres Therapeutics: Product Portfolio, Microbiome Therapeutics
  • Table 10.16: Synthetic Biologics: Product Portfolio, Microbiome Therapeutics
  • Table 13.1: Microbiome Therapies: Distribution by Phase of Development
  • Table 13.2: Microbiome Therapies: Distribution by Type of Product
  • Table 13.3: Microbiome Therapies: Distribution by Geography
  • Table 13.4: Microbiome Therapies: Distribution by Therapeutic Area
  • Table 13.5: Microbiome Therapeutics: Distribution by Therapeutic Area and Phase of Development
  • Table 13.6: Microbiome Therapeutics: Active Industry Players
  • Table 13.7: Probiotic and Prebiotic Drugs: Distribution by Numbers of Products
  • Table 13.8: Probiotic and Prebiotic Drugs: Distribution by Phase of Development
  • Table 13.9: Probiotic and Prebiotic Drugs: Active Industry Players
  • Table 13.10: Probiotic and Prebiotic Drugs: Distribution by Geography
  • Table 13.11: Probiotic and Prebiotic Drugs: Active Industry Players
  • Table 13.12: Clostridium difficile Infections (CDI): Pipeline by Product Type and Development Stage
  • Table 13.13: Irritable Bowel Syndrome (IBS): Pipeline by Product Type and Development Stage
  • Table 13.14: Diabetes: Pipeline by Product Type and Development Stage
  • Table 13.15: Number of Funding Instances by Year, 2005 Onwards
  • Table 13.16: Amount Invested by Year, 2005 Onwards
  • Table 13.17: Funding Instances: Distribution by Type, 2005-2015
  • Table 13.18: Funding Instances: Distribution by Total Amount Invested, 2005-2015 (USD Million)
  • Table 13.19: Most Active Players: Distribution by Number of Funding Instances, 2005-2015
  • Table 13.20: Most Active VC Firms/Investors: Distribution by Number of Instances, 2005-2015
  • Table 13.21: Funding Instances: Distribution by Type of Application
  • Table 13.22: Funding Instances: Distribution by Type of Product
  • Table 13.23: Recent Collaborations: Distribution by Year
  • Table 13.24: Recent Collaborations: Distribution by Type of Application
  • Table 13.25: Recent Collaborations: Distribution by Type of Therapeutic Product
  • Table 13.26: Recent Collaborations: Distribution by Type of Model
  • Table 13.27: Recent Collaborations: Distribution by Company
  • Table 13.28: Microbiome Therapeutics Market Forecast (USD Million), Short Term, Base Case, 2015-2022
  • Table 13.29: Microbiome Therapeutics Market Forecast (USD Million), Short Term, Conservative Case, 2015-2022
  • Table 13.30: Microbiome Therapeutics Market Forecast (USD Million), Short Term, Optimistic Case, 2015-2022
  • Table 13.31: Microbiome Therapeutics Market Forecast (USD Million), Mid-Long Term, Base Case, 2022-2030
  • Table 13.32: Microbiome Therapeutics Market Forecast (USD Million), Mid-Long Term, Conservative Case, 2022-2030
  • Table 13.33: Microbiome Therapeutics Market Forecast (USD Million), Mid-Long Term, Optimistic Case, 2022-2030
  • Table 13.34: Microbiome Therapeutics Market: Distribution by Therapeutic Area, 2025, 2030
  • Table 13.35: Microbiome Therapeutics Market: Distribution by Function, 2030
  • Table 13.36: OpenBiome: Revenues 2014, Distribution by Different Segments (USD Million)
  • Table 13.37: Microbiome Therapeutics Market (USD million), 2015, 2022, 2030

List of Companies

The following companies and institutes have been mentioned in this report.

  • 1. 4D Pharma
  • 2. AbbVie
  • 3. ActoGeniX
  • 4. Admera Health
  • 5. Advanced Technology Ventures
  • 6. Advancing Bio
  • 7. AgBiome
  • 8. AOBiome
  • 9. APC Microbiome Institute
  • 10. Assembly Biosciences
  • 11. Avid Biotics
  • 12. Azitra
  • 13. Baylor College of Medicine
  • 14. Beth Israel Deaconess Medical Center
  • 15. Bill and Melinda Gates Foundation
  • 16. BioAster Technology Research Institute
  • 17. BioBalance Corporation
  • 18. Biocartis
  • 19. BioConsortia
  • 20. BioGaia
  • 21. Biomecite Diagnostics
  • 22. Boston Children's Hospital
  • 23. Boston Medical Center
  • 24. Brigham and Women's Hospital
  • 25. Bright Medicine Clinic
  • 26. Broad Institute
  • 27. BTER Foundation
  • 28. C3 Jian
  • 29. Cedars-Sinai Medical Center (CSMC)
  • 30. Center for Disease Control and Prevention
  • 31. Cipac Therapeutics
  • 32. c-LECta
  • 33. Cleveland Clinic
  • 34. Companion PBx
  • 35. Concorde Medical Group
  • 36. Crohn's and Colitis Foundation of America (CCFA)
  • 37. Commonwealth Scientific and Industrial Research Organisation(CSIRO)
  • 38. Dairy Innovation Australia Limited (DIAL)
  • 39. Da Volterra
  • 40. Danisco
  • 41. Debiopharm
  • 42. Defence Advanced Research Projects Agency (DARPA)
  • 43. Dermala
  • 44. Duke University
  • 45. Enso Ventures
  • 46. Enterologics
  • 47. Enterome BioScience
  • 48. Epibiome
  • 49. Epiva Therapeutics
  • 50. Evelo Therapeutics
  • 51. Evolve Biosystems
  • 52. Evotec
  • 53. ExeGi Pharma
  • 54. Center for Biologics Evaluation and Research (CBER)
  • 55. Flagship Ventures
  • 56. Food and Agricultural Organisation (FAO)
  • 57. FUJIFILM Diosynth Biotechnologies
  • 58. Gallinee
  • 59. Genetic Analysis
  • 60. Genewiz
  • 61. GMU Microbiome Analysis Center (MBAC)
  • 62. GT Biologics
  • 63. Gustave Roussy
  • 64. Hadassah Medical Center
  • 65. Hospital Oberndorf
  • 66. Human Longevity
  • 67. Hy Laboratories
  • 68. Institute of Cardio metabolism and Nutrition (ICAN)
  • 69. Igen Biotech Group
  • 70. Illumina Accelerator
  • 71. Immune Biologics
  • 72. Immuron
  • 73. Indiana University
  • 74. Intrexon
  • 75. Inocucor Technologies
  • 76. INRA National Institute for Agronomic Research
  • 77. Inserm
  • 78. Institut De Recherche Pour Le Developent (IRD)
  • 79. Institut Merieux
  • 80. Institute for Biomedical Research Dr JosepTrueta of Girona
  • 81. International Agency for Research on Cancer (IARC)
  • 82. J. Craig Venter Institute
  • 83. Janssen
  • 84. Johnson & Johnson Innovation Center
  • 85. Kindstar Global
  • 86. KOLUPOHAKU TECHNOLOGIES (KPT)
  • 87. Lille Teaching Hospital (CHRU)
  • 88. Lundbeckfond Ventures
  • 89. MaaT Pharma
  • 90. Macau University of Science and Technology
  • 91. Manzo Pharmaceuticals
  • 92. Matatu
  • 93. Mayo Clinic
  • 94. MBcure
  • 95. Medical University Innsbruck
  • 96. Merck
  • 97. Metabiomics
  • 98. Metabogen
  • 99. Metabolon
  • 100. Metanome
  • 101. Metrodora Therapeutics
  • 102. Microbiome
  • 103. Microbiome Diagnostics
  • 104. MicroBiome Therapeutics
  • 105. Microbiota Company
  • 106. MiOmics
  • 107. Miyarisan Pharmaceutical
  • 108. Monarch Labs
  • 109. Monash University
  • 110. MonterFiore Medical Research Center of Connecticut
  • 111. Morgenthaler
  • 112. MyBiotics
  • 113. National Center for Health Statistics (NCHS)
  • 114. National Health Service (NHS)
  • 115. National Institute of Allergic and Infectious Diseases (NIAID)
  • 116. National Institute of Health (NIH)
  • 117. NIZO Food Research
  • 118. Novartis
  • 119. OmniBiome Therapeutics
  • 120. One Way Liver
  • 121. OpenBiome
  • 122. OptiBiotix Health
  • 123. Oragenics
  • 124. Osel
  • 125. OxThera
  • 126. Pasteur Institute
  • 127. Pfizer
  • 128. Pivot Bio
  • 129. Prev AbR
  • 130. Procarta Biosystems
  • 131. PureFlora
  • 132. Quorum Innovations
  • 133. Rebiotix
  • 134. Ritter Pharmaceuticals
  • 135. Rush University Medical Center
  • 136. Second Genome
  • 137. Sen Nuo Wei Biotechnology
  • 138. Seres Therapeutics
  • 139. Servier
  • 140. Seventure
  • 141. Shire
  • 142. Shoreline Biome
  • 143. Sigma-Tau Pharmaceuticals
  • 144. SporeGen
  • 145. Swecure
  • 146. Symberix
  • 147. Symbiota
  • 148. Symbiotix Biotherapies
  • 149. Synlogic
  • 150. Synthetic Biologics
  • 151. TargEDys
  • 152. Therapeutic Solutions International
  • 153. TriPhase Pharmaceuticals
  • 154. Universal Stabilisation Technologies
  • 155. Universite Pierre Et Marie Curie (UPMC)
  • 156. University of California, San Diego (UCSD)
  • 157. University of Chicago
  • 158. University of Guelph
  • 159. University of Maryland (UM) Ventures
  • 160. University of Rome Tor Vergata
  • 161. University of Virginia
  • 162. UAS Labs
  • 163. Vaiomer
  • 164. Vedanta Biosciences
  • 165. Virginia Commonwealth University
  • 166. ViroPharma Incorporated
  • 167. Vithera Pharmaceuticals
  • 168. VSL Pharmaceuticals
  • 169. Washington University School of Medicine
  • 170. Wavepoint Ventures
  • 171. Weizmann Institute
  • 172. Whole Biome
  • 173. World Gastroenterology Organisation (WGO)
  • 174. World Health Organisation (WHO)
  • 175. Wyss Institute
  • 176. Xycrobe Therapeutics
  • 177. Yakult Honsha
Back to Top